公司名称: |
上海波以尔化工有限公司 |
联系电话: |
Mr Qiu 86-21-50182298(Domestic Market)Miss Xu 86-21-50180596(Abroad Market) |
产品介绍: |
英文名称:Purvalanol A CAS:212844-53-6
|
公司名称: |
武汉易泰科技有限公司上海分公司 |
联系电话: |
86-21-50328103 * 801、802、803、804 Mobile:18930552037 |
产品介绍: |
英文名称:Purvalanol A;(2R)-2-[[6-[(3-Chlorophenyl)aMino]-9-(1-Methylethyl)-9H-purin-2-yl]aMino]-3-Methyl-1-butanol CAS:212844-53-6 纯度:99% HPLC 包装信息:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g |
公司名称: |
Ascent Scientific |
联系电话: |
4401179829988 |
产品介绍: |
英文名称:Purvalanol A CAS:212844-53-6 纯度:>98% 包装信息:1mg;10mg;50mg 备注:Potent CDK inhibitor |
公司名称: |
上海岚克医药科技发展有限公司 |
联系电话: |
0086-21-58956006,021-58950017;021-38701807 |
产品介绍: |
英文名称:Purvalanol A CAS:212844-53-6 纯度:98% 包装信息:1KG;10KG 备注:100g/1kg大量均可 |
公司名称: |
BOC Sciences |
联系电话: |
1-631-504-6093 |
产品介绍: |
英文名称:Purvalanol A CAS:212844-53-6
|
|
中文名称: | PURVALANOL A | 中文同义词: | | 英文名称: | PURVALANOL A | 英文同义词: | PURVALANOL A;NG-60;6-(3-CHLOROANILINO)-2(1R)-ISOPROPYL-2-HYDROXYETHYLAMINO-9-ISOPROPYLPURINE;(2R)-2-[[6-[(3-CHLOROPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL;2-(1R-ISOPROPOYL-2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9-ISOPROPYLPURINE;2-(1R-ISOPROPYL-2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9-ISOPROPYL-PURINE;CH61386;2R)-2-[[6-[(3-Chlorophenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanolCDKinhibitor. | CAS号: | 212844-53-6 | 分子式: | C19H25ClN6O | 分子量: | 388.89 | EINECS号: | | 相关类别: | Signalling;抑制剂 |
储存条件 | −20°C
| 溶解度 | methylene chloride: 50 mg/mL, clear, colorless
| form | powder
| color | off-white
|
生物活性 | Purvalanol A 是一种有效的,细胞渗透性 CDK 抑制剂,对cdc2-cyclin B,cdk2-cyclin A,cdk2-cyclin E,和 cdk4-cyclin D1的 IC50 分别为 4 nM,70 nM,35 nM,和 850 nM。 | 体外研究 | Purvalanol A decreases cell viability in dose-dependent manner in MCF-7 and MDA-MB-231 cell lines. Purvalanol A induces cell viability loss by 50 % in MCF-7 cells but MDA-MB-231 cells sre less sensitive to Purvalanol A (32 % decreases in cell viability). Purvalanol A induces mitochondria-mediated apoptosis in MCF-7 and MDA-MB-231 cells. Purvalanol A effectively prevents c-Src-mediated transformation by inhibiting both cell cycle progression and c-Src signaling, and effectively suppresses the anchorage independent growth of some human cancer cells in which c-Src is up-regulated. Purvalanol A has a stronger inhibitory effect on the anchorage-independent growth of HT29 and SW480 human colon cancer cells. |
|